Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861631 | 0.93 | NPC1 (0.41) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL18732358 | 0.92 | PRMT3 (0.43) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL26029016 | 0.89 | ALOX5 (0.43) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL18391393 | 0.87 | PRMT3 (0.44) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL24624490 | 0.85 | ALOX5 (0.50) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL20362359 | 0.85 | NPC1 (0.56) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL19976225 | 0.81 | ALOX5 (0.54) | NPC1RAB9AKDM4EMAPTMEN1 | |
| SCHEMBL18871162 | 0.78 | NPC1 (0.54) | NPC1RAB9AKDM4EMAPTCASP3 | |
| SCHEMBL18766695 | 0.74 | ALOX5 (0.39) | NPC1RAB9AMAPTCYP1A2DYRK1A | |
| SCHEMBL18769185 | 0.73 | PRMT3 (0.42) | PRMT3EHMT2PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10183940-B2 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-22 | — | — | US | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BRD4, BRD3, BICRA | NPC1 2985/4885RAB9A 3592/4885KDM4E 94/4885 |
| US-10183940-B2 | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR5 | NPC1 2222/4885RAB9A 3235/4885KDM4E 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.